Lorna Warwick – VJRegenMed

Supporting patients through CAR T-cell therapy

admin_vjr_user — Fri, 26 Feb 2021 14:08:24 +0000

Lorna Warwick, Lymphoma Coalition, Toronto, Canada, shares her highlights from the group discussion on the ethics of CAR T-cell therapy. Ms Warwick reveals that although CAR T-cell therapy works well and results in lasting remissions for just over 40% of patients, we still don’t know how to predict which patients it will work best for. Therefore, it is important to inform patients about realistic outcomes and ensure patients have a team ready to support them through the process. In addition, Ms Warwick discusses the role of patient organizations in educating and supporting patients through CAR T-cell therapy. This interview took place during the 3rd European CAR T-cell Meeting.

The impact of patient education on health outcomes for CAR T-cell therapy

admin_vjr_user — Fri, 26 Feb 2021 14:08:24 +0000

Lorna Warwick, Lymphoma Coalition, Toronto, Canada, discusses the importance of education in improving confidence, understanding of side effects and knowing when to seek help and support for patients due to start CAR-T therapy. Minor side effects, which could have a big impact on patients’ lives, should not be overlooked when educating patients about CAR T-cell therapy. Additionally, patients should be given an explanation about the treatment they will undergo. Addressing these factors and ensuring patients are well informed about CAR T-cell therapy can result in better health outcomes. This interview took place during the 3rd European CAR T-cell Meeting.

The effect of COVID-19 on the experience of lymphoma patients undergoing CAR-T therapy

admin_vjr_user — Fri, 26 Feb 2021 14:08:24 +0000

Lorna Warwick, Lymphoma Coalition, Toronto, Canada, discusses the impact of COVID-19 on the mental health and access to treatment of lymphoma patients in Asia. The responses of lymphoma patients in 2018 and 2020 were used to gain insight into the patient experience before and during the COVID-19 pandemic. Key findings included increased levels of anxiety and isolation, as well as difficulty accessing care, during 2020 compared to 2018. This interview took place during the 3rd European CAR T-cell Meeting.